{
    "clinical_study": {
        "@rank": "35295", 
        "arm_group": [
            {
                "arm_group_label": "Minimally Invasive Lumbar Decompression (MILD)", 
                "arm_group_type": "Active Comparator", 
                "description": "Image guided minimally-invasive lumbar decompression"
            }, 
            {
                "arm_group_label": "Epidural Steroid Injection (ESI)", 
                "arm_group_type": "Active Comparator", 
                "description": "An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine."
            }
        ], 
        "brief_summary": {
            "textblock": "Study Objective: To compare patient outcomes following treatment with either the MILD\n      procedure or epidural steroid injections (ESIs) in patients with painful lumbar spinal\n      stenosis exhibiting neurogenic claudication and having verified ligamentum flavum\n      hypertrophy as a contributing factor."
        }, 
        "brief_title": "The MiDAS ENCORE Study", 
        "condition": "Spinal Stenosis, Lumbar Region, With Neurogenic Claudication", 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Spinal Stenosis", 
                "Intermittent Claudication"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 65 years or older and a Medicare beneficiary.\n\n          2. Patients experiencing neurogenic claudication symptoms for at least 3 months duration\n             which has failed to respond or poorly responded to physical therapy, home exercise\n             programs, and oral analgesics.\n\n          3. LSS with neurogenic claudication diagnosed via:\n\n               1. Symptomatic diagnosis and\n\n               2. Radiologic evidence of LSS with unilateral or bilateral ligamentum flavum >2.5mm\n                   confirmed by pre-op MRI or CT performed within 12 months of baseline visit.\n\n          4. Patients with comorbid conditions commonly associated with spinal stenosis, such as\n             osteophytes, facet hypertrophy, minor spondylolisthesis, foraminal stenosis, and/or\n             disk protrusion may be included unless the treating physician has determined that the\n             condition is too advanced.\n\n          5. Available to complete 6 month and one year follow-up visits.\n\n        Exclusion Criteria:\n\n          1. ODI Score < 31 (0-100 ODI Scale).\n\n          2. NPRS Score < 5 (0-10 NPRS Scale).\n\n          3. Prior surgery at any treatment level.\n\n          4. History of recent spinal fractures with current related pain symptoms.\n\n          5. Patients with Grade III or higher spondylolisthesis.\n\n          6. Motor deficit or disabling back and/or leg pain from causes other than LSS neurogenic\n             claudication (e.g., acute compression fracture, metabolic neuropathy, or vascular\n             claudication symptoms, etc.).\n\n          7. Unable to walk \u2265 10 feet unaided before being limited by pain.  In this context,\n             'unaided' means without the use of a cane, walker, railing, wall, another person or\n             any other means of walking assistance.\n\n          8. Patients previously randomized and/or treated in this clinical study.\n\n          9. Patients that have previously received the MILD procedure.\n\n         10. ESI during eight weeks prior to study enrollment.\n\n         11. Epidural lipomatosis (if it is deemed to be a significant contributor of canal\n             narrowing by the physician).\n\n         12. On (or pending) Workman's Compensation or known to be considering litigation\n             associated with back pain."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093520", 
            "org_study_id": "MiDAS ENCORE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Minimally Invasive Lumbar Decompression (MILD)", 
                "description": "The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild\u00ae Device Kit is utilized to access, capture and remove bone and tissue.", 
                "intervention_name": "Minimally Invasive Lumbar Decompression", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "MILD lumbar decompression", 
                    "MILD procedure"
                ]
            }, 
            {
                "arm_group_label": "Epidural Steroid Injection (ESI)", 
                "description": "Injection of epidural steroids into the lumbar spine", 
                "intervention_name": "Epidural Steroid Injection", 
                "intervention_type": "Drug", 
                "other_name": "ESI"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lumbar Spinal Stenosis", 
            "Spinal Stenosis", 
            "Neurogenic Claudication"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "vjohnson@uspineinstitute.com", 
                    "last_name": "Vance Z Johnson, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Murrieta", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92563"
                    }, 
                    "name": "The Spine Institute"
                }, 
                "investigator": {
                    "last_name": "Vance Z Johnson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "SLi@premierpain.com", 
                    "last_name": "Sean Li, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Shrewsbury", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07702"
                    }, 
                    "name": "Premier Pain"
                }, 
                "investigator": {
                    "last_name": "Sean Li, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "MILD\u00ae Percutaneous Image-Guided Lumbar Decompression Versus Epidural Steroid Injections in Patients With Lumbar Spinal Stenosis Exhibiting Neurogenic Claudication", 
        "other_outcome": {
            "description": "Proportion of ZCQ Responders from baseline to one year follow-up in each of the two treatment groups using validated Minimal Important Change value as the clinically significant efficacy threshold.", 
            "measure": "Zurich Claudication Questionnaire (ZCQ)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "ramsinbenyamin@yahoo.com", 
            "last_name": "Ramsin Benyamin, MD"
        }, 
        "overall_contact_backup": {
            "email": "peterstaats@hotmail.com", 
            "last_name": "Peter Staats, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "AAPM; ASIPP; ISIS; ASA", 
                "last_name": "Ramsin Benyamin, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AAPM; ASIPP; ASA", 
                "last_name": "Peter Staats, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Statistical superiority of the proportion of ODI Responders from baseline to one year follow-up in the treatment group versus the proportion of ODI Responders from baseline to one year follow-up in the control group.  ODI Responders are defined as those patients achieving the validated Minimal Important Change in ODI score from baseline to follow-up as a clinically significant efficacy threshold.", 
            "measure": "Oswestry Disability Index (ODI)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093520"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Proportion of NPRS Responders from baseline to one year follow-up in each of the two treatment groups using validated Minimal Important Change value as the clinically significant efficacy threshold.", 
            "measure": "Numeric Pain Rating Scale (NPRS)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Vertos Medical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertos Medical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}